Video

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

Author(s):

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Related Videos
Laura J. Chambers, DO
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Lorenza Rimassa, MD
Domenica Lorusso, MD, PhD
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Domenica Lorusso, MD, PhD
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Related Content
The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Joyce N. Barlin, MD, Women’s Cancer Care Associates
October 7th 2024

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Angeles Secord, MD, MHSc, of Duke Cancer Institute
September 29th 2024

Mirvetuximab Soravtansine Gains Traction in Heavily Pretreated FRα+ Platinum-Sensitive Ovarian Cancer

Roopal Thakkar, MD
September 20th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer